These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15535844)

  • 41. Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.
    Kwiatkowska E; Skasko E; Niwinska A; Wojciechowska-Lacka A; Rachtan J; Molong L; Nowakowska D; Konopka B; Janiec-Jankowska A; Paszko Z; Steffen J
    Neoplasma; 2006; 53(4):305-8. PubMed ID: 16830057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study.
    Mellemkjaer L; Dahl C; Olsen JH; Bertelsen L; Guldberg P; Christensen J; Børresen-Dale AL; Stovall M; Langholz B; Bernstein L; Lynch CF; Malone KE; Haile RW; Andersson M; Thomas DC; Concannon P; Capanu M; Boice JD; ; Bernstein JL
    Br J Cancer; 2008 Feb; 98(4):728-33. PubMed ID: 18253122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
    Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
    Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
    Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
    Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population.
    Marouf C; Hajji O; Diakité B; Tazzite A; Jouhadi H; Benider A; Nadifi S
    Springerplus; 2015; 4():38. PubMed ID: 25674498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The CHEK2 1100delC variant in Swedish colorectal cancer.
    Djureinovic T; Lindblom A; Dalén J; Dedorson S; Edler D; Hjern F; Holm J; Lenander C; Lindforss U; Lundqvist N; Olivecrona H; Olsson L; Påhlman L; Rutegård J; Smedh K; Törnqvist A; Eiberg H; Bisgaard ML
    Anticancer Res; 2006; 26(6C):4885-8. PubMed ID: 17214356
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CHEK2:1100delC and female breast cancer in the United States.
    Mateus Pereira LH; Sigurdson AJ; Doody MM; Pineda MA; Alexander BH; Greene MH; Struewing JP
    Int J Cancer; 2004 Nov; 112(3):541-3. PubMed ID: 15382084
    [No Abstract]   [Full Text] [Related]  

  • 48. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer.
    Skasko E; Kluska A; Niwińska A; Kwiatkowska E; Bałabas A; Piatkowska M; Dabrowska M; Nowakowska D; Pieńkowski T
    Onkologie; 2009 Apr; 32(4):182-8. PubMed ID: 19372713
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.
    Thirthagiri E; Cheong LS; Yip CH; Teo SH
    Fam Cancer; 2009; 8(4):355-8. PubMed ID: 19399639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
    Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
    J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of familial male breast cancer for germline mutations in CHEK2.
    Sodha N; Wilson C; Bullock SL; Phillimore H; Houlston RS; Eeles RA
    Cancer Lett; 2004 Nov; 215(2):187-9. PubMed ID: 15488637
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer.
    Weischer M; Nordestgaard BG; Pharoah P; Bolla MK; Nevanlinna H; Van't Veer LJ; Garcia-Closas M; Hopper JL; Hall P; Andrulis IL; Devilee P; Fasching PA; Anton-Culver H; Lambrechts D; Hooning M; Cox A; Giles GG; Burwinkel B; Lindblom A; Couch FJ; Mannermaa A; Grenaker Alnæs G; John EM; Dörk T; Flyger H; Dunning AM; Wang Q; Muranen TA; van Hien R; Figueroa J; Southey MC; Czene K; Knight JA; Tollenaar RA; Beckmann MW; Ziogas A; Christiaens MR; Collée JM; Reed MW; Severi G; Marme F; Margolin S; Olson JE; Kosma VM; Kristensen VN; Miron A; Bogdanova N; Shah M; Blomqvist C; Broeks A; Sherman M; Phillips KA; Li J; Liu J; Glendon G; Seynaeve C; Ekici AB; Leunen K; Kriege M; Cross SS; Baglietto L; Sohn C; Wang X; Kataja V; Børresen-Dale AL; Meyer A; Easton DF; Schmidt MK; Bojesen SE
    J Clin Oncol; 2012 Dec; 30(35):4308-16. PubMed ID: 23109706
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.
    Chen W; Yurong S; Liansheng N
    Adv Ther; 2008 May; 25(5):496-501. PubMed ID: 18484200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes.
    Nagel JH; Peeters JK; Smid M; Sieuwerts AM; Wasielewski M; de Weerd V; Trapman-Jansen AM; van den Ouweland A; Brüggenwirth H; van I Jcken WF; Klijn JG; van der Spek PJ; Foekens JA; Martens JW; Schutte M; Meijers-Heijboer H
    Breast Cancer Res Treat; 2012 Apr; 132(2):439-48. PubMed ID: 21614566
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
    van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
    J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Missense mutations (p.H371Y, p.D438Y) in gene CHEK2 are associated with breast cancer risk in women of Balochistan origin.
    Baloch AH; Daud S; Raheem N; Luqman M; Ahmad A; Rehman A; Shuja J; Rasheed S; Ali A; Kakar N; Naseeb HK; Mengal MA; Awan MA; Wasim M; Baloch DM; Ahmad J
    Mol Biol Rep; 2014 Feb; 41(2):1103-7. PubMed ID: 24390236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.
    Zhang S; Phelan CM; Zhang P; Rousseau F; Ghadirian P; Robidoux A; Foulkes W; Hamel N; McCready D; Trudeau M; Lynch H; Horsman D; De Matsuda ML; Aziz Z; Gomes M; Costa MM; Liede A; Poll A; Sun P; Narod SA
    Cancer Res; 2008 Apr; 68(7):2154-7. PubMed ID: 18381420
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.
    Broeks A; de Witte L; Nooijen A; Huseinovic A; Klijn JG; van Leeuwen FE; Russell NS; van't Veer LJ
    Breast Cancer Res Treat; 2004 Jan; 83(1):91-3. PubMed ID: 14997059
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women.
    Novak DJ; Chen LQ; Ghadirian P; Hamel N; Zhang P; Rossiny V; Cardinal G; Robidoux A; Tonin PN; Rousseau F; Narod SA; Foulkes WD
    BMC Cancer; 2008 Aug; 8():239. PubMed ID: 18706089
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
    Schmidt MK; Hogervorst F; van Hien R; Cornelissen S; Broeks A; Adank MA; Meijers H; Waisfisz Q; Hollestelle A; Schutte M; van den Ouweland A; Hooning M; Andrulis IL; Anton-Culver H; Antonenkova NN; Antoniou AC; Arndt V; Bermisheva M; Bogdanova NV; Bolla MK; Brauch H; Brenner H; Brüning T; Burwinkel B; Chang-Claude J; Chenevix-Trench G; Couch FJ; Cox A; Cross SS; Czene K; Dunning AM; Fasching PA; Figueroa J; Fletcher O; Flyger H; Galle E; García-Closas M; Giles GG; Haeberle L; Hall P; Hillemanns P; Hopper JL; Jakubowska A; John EM; Jones M; Khusnutdinova E; Knight JA; Kosma VM; Kristensen V; Lee A; Lindblom A; Lubinski J; Mannermaa A; Margolin S; Meindl A; Milne RL; Muranen TA; Newcomb PA; Offit K; Park-Simon TW; Peto J; Pharoah PD; Robson M; Rudolph A; Sawyer EJ; Schmutzler RK; Seynaeve C; Soens J; Southey MC; Spurdle AB; Surowy H; Swerdlow A; Tollenaar RA; Tomlinson I; Trentham-Dietz A; Vachon C; Wang Q; Whittemore AS; Ziogas A; van der Kolk L; Nevanlinna H; Dörk T; Bojesen S; Easton DF
    J Clin Oncol; 2016 Aug; 34(23):2750-60. PubMed ID: 27269948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.